Copley to Merge with Ignite Proteomics at $150M Enterprise Value

Copley Acquisition Corp, a special purpose acquisition company, has entered into a definitive business combination agreement with Ignite Proteomics, a leader in pathway-level protein analytics for precision oncology. Upon closing, the combined entity will be named Ignite Proteomics Holdings, Inc. and will be listed on the New York Stock Exchange. The transaction values Ignite Proteomics at a pro forma enterprise value of $150 million and is expected to close in the second half of 2026, providing the company with a public platform and financial backing to scale its commercial infrastructure.